Lybrate is India’s first and largest online doctor consultation platform. By seamlessly connecting doctors and patients through our health app and making them communicate using mobile phones, we make healthcare more accessible. Join us on our mission to change the way healthcare is delivered in India.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

ANTHOS THERAPEUTICS ANNOUNCES THAT ABELACIMAB HAS RECEIVED FDA FAST TRACK DESIGNATION FOR THE TREATMENT OF THROMBOSIS ASSOCIATED WITH CANCER

Anthos Therapeutics | July 11, 2022

news image

Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, announced that the U.S. Food and Drug Administration has granted Fast Track Designation to its investigational Factor XI inhibitor, abelacimab, for the treatment of thrombosis associated with cancer. The company will also be announcing this important milestone today at a session of the ongoing 2022 Congress of the International Society on Thrombosis and Haemostas...

Read More

ORI BIOTECH RAISES $30 MILLION $30 MILLION SERIES A FINANCING ROUND TO ADVANCE INNOVATION IN CELL AND GENE THERAPY MANUFACTURING

Ori Biotech | October 15, 2020

news image

Ori Biotech Ltd (Ori), a leading innovator in cell and gene therapy (CGT) manufacturing, today announced the successful close of a $30 million Series A financing round, bringing the company's total funding to date to $41 million. The new funding will be used to help bring Ori's innovative manufacturing platform to the market. The Ori platform delivers scalable solutions to flexibly address the critical clinical and commercial manufacturing needs of CGT developers. The Series A investor s...

Read More

ILLUMINA INTRODUCES NEW PAN-CANCER COMPANION DIAGNOSTIC TO MATCH PATIENTS WITH RARE GENETIC MUTATIONS TO TARGETED THERAPY

Illumina | May 27, 2022

news image

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the addition of a companion diagnostic (CDx) indication to its CE-marked in vitro diagnostic TruSight™ Oncology (TSO) Comprehensive (EU) test. This single test kit, recently launched across Europe, assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer. The CDx pan-cancer indication will allow identification of cancer patien...

Read More

REGENERON STARTS PHASE REGN-COV2 PHASE 3 COVID-19 PREVENTION TRIAL

Regeneron | July 07, 2020

news image

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the initiation of late-stage clinical trials evaluating REGN-COV2, Regeneron's investigational double antibody cocktail for the treatment and prevention of COVID-19. A Phase 3 trial will evaluate REGN-COV2's ability to prevent infection among uninfected people who have had close exposure to a COVID-19 patient (such as the patient's housemate), and is being run jointly with the National Institute of Allergy and Infectious ...

Read More
news image

INDUSTRIAL IMPACT

ANTHOS THERAPEUTICS ANNOUNCES THAT ABELACIMAB HAS RECEIVED FDA FAST TRACK DESIGNATION FOR THE TREATMENT OF THROMBOSIS ASSOCIATED WITH CANCER

Anthos Therapeutics | July 11, 2022

Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, announced that the U.S. Food and Drug Administration has granted Fast Track Designation to its investigational Factor XI inhibitor, abelacimab, for the treatment of thrombosis associated with cancer. The company will also be announcing this important milestone today at a session of the ongoing 2022 Congress of the International Society on Thrombosis and Haemostas...

Read More
news image

ORI BIOTECH RAISES $30 MILLION $30 MILLION SERIES A FINANCING ROUND TO ADVANCE INNOVATION IN CELL AND GENE THERAPY MANUFACTURING

Ori Biotech | October 15, 2020

Ori Biotech Ltd (Ori), a leading innovator in cell and gene therapy (CGT) manufacturing, today announced the successful close of a $30 million Series A financing round, bringing the company's total funding to date to $41 million. The new funding will be used to help bring Ori's innovative manufacturing platform to the market. The Ori platform delivers scalable solutions to flexibly address the critical clinical and commercial manufacturing needs of CGT developers. The Series A investor s...

Read More
news image

ILLUMINA INTRODUCES NEW PAN-CANCER COMPANION DIAGNOSTIC TO MATCH PATIENTS WITH RARE GENETIC MUTATIONS TO TARGETED THERAPY

Illumina | May 27, 2022

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the addition of a companion diagnostic (CDx) indication to its CE-marked in vitro diagnostic TruSight™ Oncology (TSO) Comprehensive (EU) test. This single test kit, recently launched across Europe, assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer. The CDx pan-cancer indication will allow identification of cancer patien...

Read More
news image

REGENERON STARTS PHASE REGN-COV2 PHASE 3 COVID-19 PREVENTION TRIAL

Regeneron | July 07, 2020

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the initiation of late-stage clinical trials evaluating REGN-COV2, Regeneron's investigational double antibody cocktail for the treatment and prevention of COVID-19. A Phase 3 trial will evaluate REGN-COV2's ability to prevent infection among uninfected people who have had close exposure to a COVID-19 patient (such as the patient's housemate), and is being run jointly with the National Institute of Allergy and Infectious ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us